메뉴 건너뛰기




Volumn 6, Issue 6, 2006, Pages 598-605

GLP-1 and type 2 diabetes: physiology and new clinical advances

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 1 [5,6,7,8 TETRAHYDRO 3 (TRIFLUOROMETHYL) 1,2,4 TRIAZOLO[4,3 A]PYRAZIN 7 YL] 4 (2,4,5 TRIFLUOROPHENYL) 1 BUTANONE; BIM 51077; CJC 1131; CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR STIMULATING AGENT; GLUCOSE; GW 823093; HORMONE RECEPTOR AFFECTING AGENT; HORMONE RECEPTOR STIMULATING AGENT; INCRETIN; LIRAGLUTIDE; METFORMIN; NEW DRUG; PEPTIDE HYDROLASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PSN 9301; RO 0730699; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; SYR 322; TA 6666; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN; ZP 10;

EID: 33750521829     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.08.003     Document Type: Review
Times cited : (42)

References (61)
  • 1
    • 0029909112 scopus 로고    scopus 로고
    • Normalization of insulin response to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM
    • Rachman J., Gribble F.M., Barrow B.A., Levy J.C., Buchanan K.D., and Turner R.C. Normalization of insulin response to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45 (1996) 1524-1530
    • (1996) Diabetes , vol.45 , pp. 1524-1530
    • Rachman, J.1    Gribble, F.M.2    Barrow, B.A.3    Levy, J.C.4    Buchanan, K.D.5    Turner, R.C.6
  • 2
    • 0027248866 scopus 로고
    • Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
    • Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., and Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 (1993) 741-744
    • (1993) Diabetologia , vol.36 , pp. 741-744
    • Nauck, M.A.1    Kleine, N.2    Orskov, C.3    Holst, J.J.4    Willms, B.5    Creutzfeldt, W.6
  • 3
    • 0030068620 scopus 로고    scopus 로고
    • Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients
    • Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., and Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81 (1996) 327-332
    • (1996) J Clin Endocrinol Metab , vol.81 , pp. 327-332
    • Willms, B.1    Werner, J.2    Holst, J.J.3    Orskov, C.4    Creutzfeldt, W.5    Nauck, M.A.6
  • 4
    • 0032976939 scopus 로고    scopus 로고
    • Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
    • Toft-Nielsen M.B., Madsbad S., and Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 (1999) 1137-1143
    • (1999) Diabetes Care , vol.22 , pp. 1137-1143
    • Toft-Nielsen, M.B.1    Madsbad, S.2    Holst, J.J.3
  • 5
    • 0037045845 scopus 로고    scopus 로고
    • Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type-2 Diabetes: a parallel-group study
    • Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type-2 Diabetes: a parallel-group study. Lancet 359 (2002) 824-830
    • (2002) Lancet , vol.359 , pp. 824-830
    • Zander, M.1    Madsbad, S.2    Madsen, J.L.3    Holst, J.J.4
  • 6
    • 0033513455 scopus 로고    scopus 로고
    • Exendin-4 stimulates both beta-cell replication and neogenesis resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
    • Xu G., Stoffers D.A., Habener J.F., and Bonneir-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
    • (1999) Diabetes , vol.48 , pp. 2270-2276
    • Xu, G.1    Stoffers, D.A.2    Habener, J.F.3    Bonneir-Weir, S.4
  • 7
    • 0035405821 scopus 로고    scopus 로고
    • GLP-1 and exendin-4 stimulate beta-cell mass neogenesis in STZ-treated newborn rats resulting in persistently improved glucose homeostasis at adult age
    • Tourrel C., Balbe D., Lacorne M., Meile M.J., Kergoat M., and Portha B. GLP-1 and exendin-4 stimulate beta-cell mass neogenesis in STZ-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50 (2001) 1562-1570
    • (2001) Diabetes , vol.50 , pp. 1562-1570
    • Tourrel, C.1    Balbe, D.2    Lacorne, M.3    Meile, M.J.4    Kergoat, M.5    Portha, B.6
  • 8
    • 0036828227 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
    • Farilla L., Hui H., Bertolotto C., Kang E., Bulotta A., Di Mario U., and Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 (2002) 4397-4408
    • (2002) Endocrinology , vol.143 , pp. 4397-4408
    • Farilla, L.1    Hui, H.2    Bertolotto, C.3    Kang, E.4    Bulotta, A.5    Di Mario, U.6    Perfetti, R.7
  • 9
    • 33748331194 scopus 로고    scopus 로고
    • Chronic inhibition of DPPIV with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes
    • Mu J., Woods J., Zhou Y.-P., Roy R.S., Li Z., Zycband E., Feng Y., Zhu L., Li C., Howard A.D., et al. Chronic inhibition of DPPIV with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006) 1695-1704
    • (2006) Diabetes , vol.55 , pp. 1695-1704
    • Mu, J.1    Woods, J.2    Zhou, Y.-P.3    Roy, R.S.4    Li, Z.5    Zycband, E.6    Feng, Y.7    Zhu, L.8    Li, C.9    Howard, A.D.10
  • 10
    • 3242730474 scopus 로고    scopus 로고
    • Role of incretin hormones in the regulation of insulin secretion in diabetic and non diabetic humans
    • Holst J.J., and Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and non diabetic humans. Am J Physiol Endocrinol Metab 287 (2004) E199-E206
    • (2004) Am J Physiol Endocrinol Metab , vol.287
    • Holst, J.J.1    Gromada, J.2
  • 11
    • 0028799007 scopus 로고
    • Differential processing of proglucagon by the subtilisin-like prohormone convertase PC2 and PC3 to generate either glucagon or glucagon-like peptide
    • Rouille Y., Martin S., and Steiner D.F. Differential processing of proglucagon by the subtilisin-like prohormone convertase PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 270 (1995) 26488-26496
    • (1995) J Biol Chem , vol.270 , pp. 26488-26496
    • Rouille, Y.1    Martin, S.2    Steiner, D.F.3
  • 12
    • 0027227370 scopus 로고
    • Glucagon-like peptide-1 (7-36) amide and glucose dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post prandial and 24h secretion patterns
    • Elliott R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., and Marks V. Glucagon-like peptide-1 (7-36) amide and glucose dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post prandial and 24h secretion patterns. J Endocrinol 138 (1993) 159-166
    • (1993) J Endocrinol , vol.138 , pp. 159-166
    • Elliott, R.M.1    Morgan, L.M.2    Tredger, J.A.3    Deacon, S.4    Wright, J.5    Marks, V.6
  • 13
    • 33644840976 scopus 로고    scopus 로고
    • Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
    • De Léon D.D., Crutchlow M.F., Nina Ham J.-Y., and Stoffers D.A. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 38 (2006) 845-859
    • (2006) Int J Biochem Cell Biol , vol.38 , pp. 845-859
    • De Léon, D.D.1    Crutchlow, M.F.2    Nina Ham, J.-Y.3    Stoffers, D.A.4
  • 14
    • 24044470321 scopus 로고    scopus 로고
    • Physiology and patho physiology of glucagon-like peptide-1: the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity and stress
    • Bojanowska E. Physiology and patho physiology of glucagon-like peptide-1: the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity and stress. Med Sci Monit 11 (2005) RA271-RA278
    • (2005) Med Sci Monit , vol.11
    • Bojanowska, E.1
  • 15
    • 33645071360 scopus 로고    scopus 로고
    • Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
    • Demonstrates that both L and K cells are present in equal numbers in human duodenum and that both express glucokinase and glucose transporters. The early rise in GLP-1 plasma levels after an oral glucose tolerance test can be caused by the presence of L cells in human duodenum.
    • Theodorakis M.J., Carlson O., Michopoulos S., Doyle M.E., Juhaszovz M., Petraki K., and Egan J.M. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 290 (2006) 550-559. Demonstrates that both L and K cells are present in equal numbers in human duodenum and that both express glucokinase and glucose transporters. The early rise in GLP-1 plasma levels after an oral glucose tolerance test can be caused by the presence of L cells in human duodenum.
    • (2006) Am J Physiol Endocrinol Metab , vol.290 , pp. 550-559
    • Theodorakis, M.J.1    Carlson, O.2    Michopoulos, S.3    Doyle, M.E.4    Juhaszovz, M.5    Petraki, K.6    Egan, J.M.7
  • 16
    • 24944577486 scopus 로고    scopus 로고
    • Alpha cell function in health and disease: influence of glucagons-like peptide-1
    • Dunning B.E., Foley J.E., and Ahren B. Alpha cell function in health and disease: influence of glucagons-like peptide-1. Diabetologia 48 (2005) 1700-1713
    • (2005) Diabetologia , vol.48 , pp. 1700-1713
    • Dunning, B.E.1    Foley, J.E.2    Ahren, B.3
  • 17
    • 15044354562 scopus 로고    scopus 로고
    • Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter
    • Larsen P.J., and Holst J.J. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept 128 (2005) 97-107
    • (2005) Regul Pept , vol.128 , pp. 97-107
    • Larsen, P.J.1    Holst, J.J.2
  • 18
    • 0141532690 scopus 로고    scopus 로고
    • A novel glucose sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line
    • Gribble F.M., Williams L., Simpson A.K., and Reimann F. A novel glucose sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52 (2003) 1147-1154
    • (2003) Diabetes , vol.52 , pp. 1147-1154
    • Gribble, F.M.1    Williams, L.2    Simpson, A.K.3    Reimann, F.4
  • 20
    • 22744442874 scopus 로고    scopus 로고
    • Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors
    • Clear summary of the history of DPPIV enzymes and a review of the development of DPPIV inhibitors as potential antidiabetics.
    • Demuth H.-U., McIntosch C.H.S., and Pederson R.A. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 1751 (2005) 33-45. Clear summary of the history of DPPIV enzymes and a review of the development of DPPIV inhibitors as potential antidiabetics.
    • (2005) Biochim Biophys Acta , vol.1751 , pp. 33-45
    • Demuth, H.-U.1    McIntosch, C.H.S.2    Pederson, R.A.3
  • 21
    • 24944436267 scopus 로고    scopus 로고
    • Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon like peptide-1 in the anaesthetised pig
    • Plamboeck A., Holst J.J., Carr R.D., and Deacon D.F. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon like peptide-1 in the anaesthetised pig. Diabetologia 48 (2005) 1882-1890
    • (2005) Diabetologia , vol.48 , pp. 1882-1890
    • Plamboeck, A.1    Holst, J.J.2    Carr, R.D.3    Deacon, D.F.4
  • 22
    • 0033696456 scopus 로고    scopus 로고
    • Portal GLP-1 administration in rats augments the insulin response to glucose by neuronal mechanisms
    • Balkan B., and Li X. Portal GLP-1 administration in rats augments the insulin response to glucose by neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279 (2000) R1449-R1454
    • (2000) Am J Physiol Regul Integr Comp Physiol , vol.279
    • Balkan, B.1    Li, X.2
  • 23
    • 0035434115 scopus 로고    scopus 로고
    • Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor
    • Burcelin R., Da Costa A., Drucker D., and Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50 (2001) 1720-1728
    • (2001) Diabetes , vol.50 , pp. 1720-1728
    • Burcelin, R.1    Da Costa, A.2    Drucker, D.3    Thorens, B.4
  • 25
    • 17844399596 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 mediates the therapeutic actions of DPPIV inhibitors
    • The authors have listed five arguments in support of GLP-1 mediating the therapeutic actions of DPPIV inhibitors.
    • Holst J.J., and Deacon C.F. Glucagon-like peptide-1 mediates the therapeutic actions of DPPIV inhibitors. Diabetologia 48 (2005) 612-615. The authors have listed five arguments in support of GLP-1 mediating the therapeutic actions of DPPIV inhibitors.
    • (2005) Diabetologia , vol.48 , pp. 612-615
    • Holst, J.J.1    Deacon, C.F.2
  • 26
    • 20044379258 scopus 로고    scopus 로고
    • Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones
    • Ionut V., Hucking K., Liberty I.F., and Bergmann R.N. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 48 (2005) 967-975
    • (2005) Diabetologia , vol.48 , pp. 967-975
    • Ionut, V.1    Hucking, K.2    Liberty, I.F.3    Bergmann, R.N.4
  • 27
    • 0942287326 scopus 로고    scopus 로고
    • Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice
    • Ahren B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol 286 (2004) R269-R272
    • (2004) Am J Physiol Regul Integr Comp Physiol , vol.286
    • Ahren, B.1
  • 28
    • 0344357096 scopus 로고
    • Glucagon-like peptide-1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line
    • Drucker D.J., Philippe J., Mojsov S., Chick W.L., and Habener J.F. Glucagon-like peptide-1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84 (1987) 3434-3438
    • (1987) Proc Natl Acad Sci USA , vol.84 , pp. 3434-3438
    • Drucker, D.J.1    Philippe, J.2    Mojsov, S.3    Chick, W.L.4    Habener, J.F.5
  • 29
    • 33646046535 scopus 로고    scopus 로고
    • Incretins and islet function
    • Ahren B. Incretins and islet function. Cur Mol Med 13 (2006) 154-161
    • (2006) Cur Mol Med , vol.13 , pp. 154-161
    • Ahren, B.1
  • 30
    • 32944473560 scopus 로고    scopus 로고
    • Therapeutic approaches to preserve islet mass in type 2 diabetes
    • Baggio L.L., and Drucker D.J. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 57 (2006) 267-281
    • (2006) Annu Rev Med , vol.57 , pp. 267-281
    • Baggio, L.L.1    Drucker, D.J.2
  • 31
    • 33748331194 scopus 로고    scopus 로고
    • Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes
    • Woods M.J., Zhou Y.P., Roy R.S., Li Z., Zycband E., Feng Y., Zhu L., Li C., Howard A.D., Moller D.E., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006) 1695-1704
    • (2006) Diabetes , vol.55 , pp. 1695-1704
    • Woods, M.J.1    Zhou, Y.P.2    Roy, R.S.3    Li, Z.4    Zycband, E.5    Feng, Y.6    Zhu, L.7    Li, C.8    Howard, A.D.9    Moller, D.E.10
  • 33
    • 7644243354 scopus 로고    scopus 로고
    • Exendin-4 dose dependently stimulates somatostatin and insulin secretion in perfused rat pancreas
    • Egido E.M., Silvestre S.A., Hernandez R., and Marco J. Exendin-4 dose dependently stimulates somatostatin and insulin secretion in perfused rat pancreas. Horm Metab Res 36 (2004) 595-600
    • (2004) Horm Metab Res , vol.36 , pp. 595-600
    • Egido, E.M.1    Silvestre, S.A.2    Hernandez, R.3    Marco, J.4
  • 34
    • 20044374696 scopus 로고    scopus 로고
    • β-cell-secretory products activate α-cell ATP dependent potassium channels to inhibit glucagons release
    • Franklin I., Gromada J., Gjinovci A., Theander S., and Wollheim C.B. β-cell-secretory products activate α-cell ATP dependent potassium channels to inhibit glucagons release. Diabetes 54 (2005) 1808-1815
    • (2005) Diabetes , vol.54 , pp. 1808-1815
    • Franklin, I.1    Gromada, J.2    Gjinovci, A.3    Theander, S.4    Wollheim, C.B.5
  • 36
    • 22144491473 scopus 로고    scopus 로고
    • Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in alzheimer's disease
    • This review compares the biochemical cascades activated by GLP-1 receptor in the pancreas and the brain, as well as the functions of GLP-1 (apoptosis versus cell survival).
    • Perry T., and Greig N.H. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in alzheimer's disease. Curr Alzheimer Res 2 (2005) 377-385. This review compares the biochemical cascades activated by GLP-1 receptor in the pancreas and the brain, as well as the functions of GLP-1 (apoptosis versus cell survival).
    • (2005) Curr Alzheimer Res , vol.2 , pp. 377-385
    • Perry, T.1    Greig, N.H.2
  • 37
    • 0036721026 scopus 로고    scopus 로고
    • Protection and reversal of exocitotoxic neuronal damage by glucagon like peptide-1 and exendin-4
    • Perry T., Haughey N.J., Mattson M.P., Egan J.M., and Greig N.H. Protection and reversal of exocitotoxic neuronal damage by glucagon like peptide-1 and exendin-4. J Pharmacol Exp Ther 302 (2002) 881-888
    • (2002) J Pharmacol Exp Ther , vol.302 , pp. 881-888
    • Perry, T.1    Haughey, N.J.2    Mattson, M.P.3    Egan, J.M.4    Greig, N.H.5
  • 38
  • 39
    • 8544258807 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
    • Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., and Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287 (2004) E1209-E1215
    • (2004) Am J Physiol Endocrinol Metab , vol.287
    • Nystrom, T.1    Gutniak, M.K.2    Zhang, Q.3    Zhang, F.4    Holst, J.J.5    Ahren, B.6    Sjoholm, A.7
  • 40
    • 4344605042 scopus 로고    scopus 로고
    • Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
    • Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., Stolarski C., Shen Y.T., and Shannon R.P. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110 (2004) 955-961
    • (2004) Circulation , vol.110 , pp. 955-961
    • Nikolaidis, L.A.1    Elahi, D.2    Hentosz, T.3    Doverspike, A.4    Huerbin, R.5    Zourelias, L.6    Stolarski, C.7    Shen, Y.T.8    Shannon, R.P.9
  • 41
    • 12144260853 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
    • Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., and Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 (2005) 146-151
    • (2005) Diabetes , vol.54 , pp. 146-151
    • Bose, A.K.1    Mocanu, M.M.2    Carr, R.D.3    Brand, C.L.4    Yellon, D.M.5
  • 42
    • 0035046251 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic b-cells by a cyclic AMP/PKA dependent mechanism
    • Wang X., Zhou J., Doyle M.E., and Egan J.M. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic b-cells by a cyclic AMP/PKA dependent mechanism. Endocrinology 142 (2001) 1820-1827
    • (2001) Endocrinology , vol.142 , pp. 1820-1827
    • Wang, X.1    Zhou, J.2    Doyle, M.E.3    Egan, J.M.4
  • 43
    • 33745315716 scopus 로고    scopus 로고
    • Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass
    • Buteau J., Spatz M.L., and Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 55 (2006) 1190-1196
    • (2006) Diabetes , vol.55 , pp. 1190-1196
    • Buteau, J.1    Spatz, M.L.2    Accili, D.3
  • 45
    • 0037386156 scopus 로고    scopus 로고
    • Glucagon like peptide-1inhibits apoptosis of insulin-secreting cells via a cyclic 5′AMP dependent protein kinase A- and a PI3K-dependent pathway
    • Hui H., Nourparvar A., Zhao X., and Perfetti R. Glucagon like peptide-1inhibits apoptosis of insulin-secreting cells via a cyclic 5′AMP dependent protein kinase A- and a PI3K-dependent pathway. Endocrinology 144 (2003) 1444-1445
    • (2003) Endocrinology , vol.144 , pp. 1444-1445
    • Hui, H.1    Nourparvar, A.2    Zhao, X.3    Perfetti, R.4
  • 46
    • 0037221488 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor
    • Buteau J., Foisy S., Joly E., and Prentki M. Glucagon-like peptide-1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52 (2003) 124-132
    • (2003) Diabetes , vol.52 , pp. 124-132
    • Buteau, J.1    Foisy, S.2    Joly, E.3    Prentki, M.4
  • 47
    • 2542479899 scopus 로고    scopus 로고
    • Minireview: glucagon like peptide-1 regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system
    • Brubaker P.L., and Drucker D.J. Minireview: glucagon like peptide-1 regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system. Endocinology 145 (2004) 2653-2659
    • (2004) Endocinology , vol.145 , pp. 2653-2659
    • Brubaker, P.L.1    Drucker, D.J.2
  • 48
    • 33745315716 scopus 로고    scopus 로고
    • Transcription factor FoxO1 mediates glucagon like peptide-1 effects on β-cell mass
    • Buteau J., Spatz M.L., and Accili D. Transcription factor FoxO1 mediates glucagon like peptide-1 effects on β-cell mass. Diabetes 55 (2006) 1190-1196
    • (2006) Diabetes , vol.55 , pp. 1190-1196
    • Buteau, J.1    Spatz, M.L.2    Accili, D.3
  • 49
    • 17144374877 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes
    • Sinclair E.M., and Drucker D.J. Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes. Curr Opin Endocrinol Diabet 12 (2005) 146-151
    • (2005) Curr Opin Endocrinol Diabet , vol.12 , pp. 146-151
    • Sinclair, E.M.1    Drucker, D.J.2
  • 50
    • 31844443202 scopus 로고    scopus 로고
    • Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
    • Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologi 49 (2006) 253-260
    • (2006) Diabetologi , vol.49 , pp. 253-260
    • Holst, J.J.1
  • 51
    • 21744433419 scopus 로고    scopus 로고
    • Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes
    • Gautier J.F., Fetita S., Sobngwi E., and Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 31 (2005) 233-242
    • (2005) Diabetes Metab , vol.31 , pp. 233-242
    • Gautier, J.F.1    Fetita, S.2    Sobngwi, E.3    Salaun-Martin, C.4
  • 52
    • 11144236233 scopus 로고    scopus 로고
    • Incretin mimetics as emerging treatment for type 2 diabetes
    • Recent review on the clinical Phase I/II trial data for exenatide and liraglutide.
    • Joy S.V., Rodgers P.T., and Scates A. Incretin mimetics as emerging treatment for type 2 diabetes. Ann Pharmacother 39 (2005) 110-118. Recent review on the clinical Phase I/II trial data for exenatide and liraglutide.
    • (2005) Ann Pharmacother , vol.39 , pp. 110-118
    • Joy, S.V.1    Rodgers, P.T.2    Scates, A.3
  • 53
    • 0037787851 scopus 로고    scopus 로고
    • Dipeptidyl peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV
    • Lambeir A.M., Durinx C., Scharpe S., and De Meester I. Dipeptidyl peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40 (2003) 209-294
    • (2003) Crit Rev Clin Lab Sci , vol.40 , pp. 209-294
    • Lambeir, A.M.1    Durinx, C.2    Scharpe, S.3    De Meester, I.4
  • 54
    • 0033579444 scopus 로고    scopus 로고
    • Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts
    • Park J.E., Lenter M.C., Zimmermann R.N., Garin-Chesa P., Old L.J., and Rettig W.J. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274 (1999) 36505-36512
    • (1999) J Biol Chem , vol.274 , pp. 36505-36512
    • Park, J.E.1    Lenter, M.C.2    Zimmermann, R.N.3    Garin-Chesa, P.4    Old, L.J.5    Rettig, W.J.6
  • 55
    • 20444421293 scopus 로고    scopus 로고
    • Fibroblast activation protein-α and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy
    • This review summarizes the evidence that FAPα and DPPIV are potential targets for cancer therapy.
    • Kelly T. Fibroblast activation protein-α and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat 8 (2005) 51-58. This review summarizes the evidence that FAPα and DPPIV are potential targets for cancer therapy.
    • (2005) Drug Resist Updat , vol.8 , pp. 51-58
    • Kelly, T.1
  • 58
    • 17844407465 scopus 로고    scopus 로고
    • The therapeutic actions of DPPIV inhibition are not mediated by glucagon-like peptide-1
    • Nauck M.A., and El-Ouaghlidi A. The therapeutic actions of DPPIV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 48 (2005) 608-611
    • (2005) Diabetologia , vol.48 , pp. 608-611
    • Nauck, M.A.1    El-Ouaghlidi, A.2
  • 59
    • 33748442464 scopus 로고    scopus 로고
    • Interim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
    • Blonde L., Kleine E.J., Han J., Zhang B., Mac S.M., Poon T.H., Taylor K.L., Trautmann M.E., Kim D.D., and Kendall D.M. Interim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8 (2006) 436-447
    • (2006) Diabetes Obes Metab , vol.8 , pp. 436-447
    • Blonde, L.1    Kleine, E.J.2    Han, J.3    Zhang, B.4    Mac, S.M.5    Poon, T.H.6    Taylor, K.L.7    Trautmann, M.E.8    Kim, D.D.9    Kendall, D.M.10
  • 60
    • 2342599057 scopus 로고    scopus 로고
    • One week's treatment with the long-acting glucagon-like derivative liraglutide (NN2211) markedly improves 24-h glycemia and a- and b-cell function and reduces endogenous glucose release in patients with type 2 diabetes
    • Degn K.B., Juhl C.B., Sturis J., Jakobsen G., Brock B., Chandramouli V., Rungby J., Landau B.R., and Schmitz O. One week's treatment with the long-acting glucagon-like derivative liraglutide (NN2211) markedly improves 24-h glycemia and a- and b-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53 (2004) 1187-1194
    • (2004) Diabetes , vol.53 , pp. 1187-1194
    • Degn, K.B.1    Juhl, C.B.2    Sturis, J.3    Jakobsen, G.4    Brock, B.5    Chandramouli, V.6    Rungby, J.7    Landau, B.R.8    Schmitz, O.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.